Back

ENA Respiratory wins AUD $2.98 million for asthma trial of INNA-051

Verifying
  • ENA Respiratory received funding for an asthma study of its INNA-051 nasal treatment.
  • AUD $2,980,000 will support the Phase Ib ENA-A-04 trial in Australia.
  • ENA Respiratory expects the randomised study to start in Q1 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.